Vitalea Science Signs Dr. Robert Ings to Its Scientific Advisory Board to Help Unravel Human Drug Performance and Metabolism with Increased Safety and Accuracy

2008-09-16 05:42:03 -

- Vitalea Science (VS) today announced the appointment Dr. Robert Ings to its Scientific Advisory Board. Dr Ings brings an impressive resume covering 30 plus years in Europe and U.S. Pharmaceutical companies and, until recently, served as Vice President of DMPK at Roche Palo Alto. He presently is founder and President of RMI-Pharmacokinetics, a pharmaceutical consultancy firm grounded by his many years of experience in bringing effective drugs to market.

Vitalea Science's core expertise lies in its unique clinical drug development platform, the BioMicadas, a type of particle accelerator developed by PSI/Zurich in collaboration with Vitalea Science. Together, RMI and VS will address two urgent industry needs for improving clinical drug evaluations: making key decisions earlier and more effectively as well as drug metabolite identification as early as the first-in-human trials.

The joint approach is validated by FDA's Critical Path Initiative to New Medical Products and their recent guidance calling for human metabolism studies to be performed much earlier in clinical drug development (www.fda.gov/cder/guidance/6897fnl.pdf).

Dr. Ings' expertise brings to bear the perfect complement of skill sets to Vitalea in the rapidly evolving field of microdosing and microtracing using the BioMicadas Accelerator technology. "We are very fortunate to have attracted his talent and look forward to a very fruitful relationship," adds Dueker, CEO of Vitalea Science, Inc.

"Vitalea's team is a proven leader in their application of AMS to the biomedical field and has assembled a formidable Scientific Advisory Board working at the cutting edge of this high potential technology. I am very excited to join them." says Dr. Ings. "Together, RMI and VS can provide advanced technologies, data analysis and interpretation to accelerate the drug development process and make it much more effective."

Dr. Ings and RMI will be working closely with Vitalea to offer technology driven solutions to bring key decisions earlier and drugs to market more efficiently than previously possible. Vitalea will be hosting an open house on October 9th, 2008 at its new Davis facility. Please go to our website (www.vitaleascience.com/companyevents.htm) or contact us for an invitation and details.

About Vitalea Science, Inc. (www.vitaleascience.com)

Vitalea is a pioneering Bioanalytical Contract Research Organization, which provides services supported by new Accelerator Mass Spectrometry technologies for exploring the pharmacokinetics and metabolism of drug candidates directly in humans, both prior to and as part of Phase I clinical trials. These avenues can accelerate a compound or class of compounds through the development process by revealing the true human physiochemistry, without reliance on extrapolation from often-irrelevant animal models or on human cellular assays that lack the full metabolism and target complement of a living person.

About RMI (www.rmi-pharmacokinetics.com)

RMI-Pharmacokinetics is dedicated to provide high quality consultative services on pharmacokinetics & drug metabolism including data analysis, data interpretation, issue resolution, strategic planning, due diligences and training, tailored specifically for the industry.

Vitalea Science, Inc.
Le Vuong, 530-341-0200
levuong@vitaleascience.com
www.vitaleascience.com